{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:47:17Z","timestamp":1791082037279,"version":"4.1.0"},"reference-count":85,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>MicroRNAs (miRNAs) are short, non-coding RNA species that are important post-transcriptional regulators of gene expression and play an important role in the pathogenesis of non-alcoholic fatty liver disease. Here, we investigated the phosphodiesterase 5 (PDE5) inhibitor induced effects on hepatic and plasma exosomal miRNA expression in CCl4-treated rats. In the present study, hepatic miRNA profiling was conducted using the Nanostring nCounter technology and mRNA profiling using RNA sequencing from PDE5 treated rats in the model of CCl4-induced liver fibrosis. To evaluate if the PDE5 inhibitor affected differentially expressed miRNAs in the liver can be detected in plasma exosomes, qRT-PCR specific assays were used. In livers from CCl4-treated rats, the expression of 22 miRNAs was significantly increased (&gt;1.5-fold, adj. p &lt; 0.05), whereas the expression of 16 miRNAs was significantly decreased (&gt;1.5-fold, adj. p &lt; 0.05). The majority of the deregulated miRNA species are implicated in fibrotic and inflammatory processes. The PDE5 inhibitor suppressed the induction of pro-fibrotic miRNAs, such as miR-99b miR-100 and miR-199a-5p, and restored levels of anti-fibrotic miR-122 and miR-192 in the liver. In plasma exosomes, we observed elevated levels of miR-99b, miR-100 and miR-142-3p after treatment with the PDE5-inhibitor compared to CCl4\/Vehicle-treated. Our study demonstrated for the first time that during the development of hepatic fibrosis in the preclinical model of CCl4-induced liver fibrosis, defined aspects of miRNA regulated liver pathogenesis are influenced by PDE5 treatment. In conclusion, miRNA profiling of plasma exosomes might be used as a biomarker for NASH progression and monitoring of treatment effects.<\/jats:p>","DOI":"10.3390\/ijms22010382","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:31:49Z","timestamp":1609425109000},"page":"382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Exosomal miRNAs as Potential Biomarkers to Monitor Phosphodiesterase 5 Inhibitor Induced Anti-Fibrotic Effects on CCl4 Treated Rats"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4768-9074","authenticated-orcid":false,"given":"Andre","family":"Broermann","sequence":"first","affiliation":[{"name":"Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Schmid","sequence":"additional","affiliation":[{"name":"Translational Medicine &amp; Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogsen","family":"Gabrielyan","sequence":"additional","affiliation":[{"name":"Translational Medicine &amp; Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Sakowski","sequence":"additional","affiliation":[{"name":"Translational Medicine &amp; Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Eisele","sequence":"additional","affiliation":[{"name":"Translational Medicine &amp; Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Keller","sequence":"additional","affiliation":[{"name":"Drug Metabolism &amp; Pharmacokinetics, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wolff","sequence":"additional","affiliation":[{"name":"Translational Medicine &amp; Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Baum","sequence":"additional","affiliation":[{"name":"Translational Medicine &amp; Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Stierstorfer","sequence":"additional","affiliation":[{"name":"Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Huber","sequence":"additional","affiliation":[{"name":"Clinical Operations, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard K.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[{"name":"Fifth Department of Medicine (Nephrology\/Endocrinology\/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8143-0579","authenticated-orcid":false,"given":"Berthold","family":"Hocher","sequence":"additional","affiliation":[{"name":"Fifth Department of Medicine (Nephrology\/Endocrinology\/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany"},{"name":"Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha 410078, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruediger","family":"Streicher","sequence":"additional","affiliation":[{"name":"Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-3134","authenticated-orcid":false,"given":"Denis","family":"Deli\u0107","sequence":"additional","affiliation":[{"name":"Translational Medicine &amp; Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Birkendorferstr.65, 88397 Biberach, Germany"},{"name":"Fifth Department of Medicine (Nephrology\/Endocrinology\/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: A review of available epidemiological data","volume":"58","author":"Blachier","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_3","first-page":"447","article-title":"Non-alcoholic fatty liver disease: Epidemiology, clinical course, investigation, and treatment","volume":"111","author":"Rau","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2036.2007.03246.x","article-title":"GI epidemiology: Nonalcoholic fatty liver disease","volume":"25","author":"Angulo","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1503\/cmaj.045232","article-title":"Nonalcoholic fatty liver disease","volume":"172","author":"Adams","year":"2005","journal-title":"CMAJ."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Piazzolla, V.A., and Mangia, A. (2020). Noninvasive Diagnosis of NAFLD and NASH. Cells, 9.","DOI":"10.3390\/cells9041005"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2010.03.052","article-title":"Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice","volume":"139","author":"Miura","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbadis.2014.07.025","article-title":"Stat3 signaling activation crosslinking of TGF-b1 in hepatic stellate cell exacerbates liver injury and fibrosis","volume":"1842","author":"Xu","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0002-9440(10)61117-0","article-title":"The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease","volume":"160","author":"Lewindon","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0960-9822(02)00809-6","article-title":"Identification of tissue-specific microRNAs from mouse","volume":"12","author":"Rauhut","year":"2002","journal-title":"Curr. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/hep.25960","article-title":"Emerging role of microRNAs in the regulation of lipid metabolism","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1172\/JCI63539","article-title":"Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver","volume":"122","author":"Hsu","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrgastro.2013.87","article-title":"MicroRNAs in liver disease","volume":"10","author":"Szabo","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.celrep.2012.10.023","article-title":"Specific miRNA stabilization by Gld2-catalyzed monoadenylation","volume":"2","author":"Gu","year":"2012","journal-title":"Cell Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2174\/1566523214666141224095610","article-title":"miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir","volume":"15","author":"Thakral","year":"2015","journal-title":"Curr. Gene. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1073\/pnas.0813371106","article-title":"Circulating microRNAs, potential biomarkers for drug-induced liver injury","volume":"106","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/1078-0432.CCR-07-0523","article-title":"Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival","volume":"14","author":"Jiang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1038\/onc.2009.211","article-title":"Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties","volume":"28","author":"Coulouarn","year":"2009","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaut.2009.02.022","article-title":"Primary biliary cirrhosis is associated with altered hepatic microRNA expression","volume":"32","author":"Padgett","year":"2009","journal-title":"J. Autoimmun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1530-0277.2009.01007.x","article-title":"MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice","volume":"33","author":"Dolganiuc","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep.22569","article-title":"Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression","volume":"48","author":"Cheung","year":"2008","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/hep.25873","article-title":"Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases","volume":"56","author":"Bala","year":"2012","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Cermelli, S., Ruggieri, A., Marrero, J.A., Ioannou, G.N., and Beretta, L. (2011). Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023937"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/MCG.0b013e3181f18ac2","article-title":"Circulating microRNAs as biomarkers for hepatocellular carcinoma","volume":"45","author":"Qu","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/hep.24538","article-title":"Circulating microRNAs as potential markers of human drug-induced liver injury","volume":"54","author":"Dear","year":"2011","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1373\/clinchem.2010.147850","article-title":"Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases","volume":"56","author":"Zhang","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.taap.2012.04.018","article-title":"Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline-and folate-deficient diet","volume":"262","author":"Tryndyak","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2008.09.066","article-title":"Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells","volume":"136","author":"Witek","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ra88","DOI":"10.1126\/scisignal.2004512","article-title":"Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells","volume":"6","author":"Povero","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sung, S., Kim, J., and Jung, Y. (2018). Liver-Derived Exosomes and Their Implications in Liver Pathobiology. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123715"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Povero, D., Eguchi, A., Li, H., Johnson, C.D., Papouchado, B.G., Wree, A., Messer, K., and Feldstein, A.E. (2014). Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0113651"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design","volume":"89","author":"Anstee","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic Landscape for NAFLD in 2020","volume":"158","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"G535","DOI":"10.1152\/ajpgi.00297.2005","article-title":"Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation","volume":"290","author":"Perri","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/bph.14137","article-title":"The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis","volume":"175","author":"Titos","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1073\/pnas.1821045116","article-title":"sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH","volume":"116","author":"Hall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1038\/s41598-018-27656-y","article-title":"The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats","volume":"8","author":"Schwabl","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1755-1536-6-19","article-title":"Experimental liver fibrosis research: Update on animal models, legal issues and translational aspects","volume":"6","author":"Liedtke","year":"2013","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Mesirov Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in nonhuman primates","volume":"452","author":"Elmen","year":"2008","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","article-title":"miR-122\u2014A key factor and therapeutic target in liver disease","volume":"2","author":"Bandiera","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/labinvest.2010.166","article-title":"Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease","volume":"91","author":"Alisi","year":"2011","journal-title":"Lab. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2013.05.021","article-title":"Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and nonalcoholic fatty liver","volume":"424","author":"Yamada","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/liv.12429","article-title":"Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease","volume":"34","author":"Miyaaki","year":"2014","journal-title":"Liver Int."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Becker, P.P., Rau, M., Schmitt, J., Malsch, C., Hammer, C., Bantel, H., M\u00fcllhaupt, B., and Geier, A. (2015). Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142661"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrurol.2014.195","article-title":"NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer","volume":"11","author":"Flores","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11549","DOI":"10.1038\/srep11549","article-title":"Integrative miRNA and Gene Expression Profiling Analysis of Human Quiescent Hepatic Stellate Cells","volume":"5","author":"Coll","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Tan, Y., Ge, G., Pan, T., Wen, D., and Gan, J. (2014). A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105192"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1042\/CS20160216","article-title":"Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury","volume":"130","author":"Roy","year":"2016","journal-title":"Clin. Sci. (Lond)"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1084\/jem.20171352","article-title":"ZEB1, ZEB2, and the miR-200 family form a counterregulatory network to regulate CD8+ T cell fates","volume":"215","author":"Guan","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lfs.2017.08.017","article-title":"MiR-142-3p blocks TGF-\u03b2-induced activation of hepatic stellate cells through targeting TGF\u03b2RI","volume":"187","author":"Yang","year":"2017","journal-title":"Life Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.omtn.2019.05.001","article-title":"miR-455-3p Alleviates Hepatic Stellate Cell Activation and Liver Fibrosis by Suppressing HSF1 Expression","volume":"16","author":"Wei","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lino Cardenas, C.L., Henaoui, I.S., Courcot, E., Roderburg, C., Cauffieiz, C., Aubert, S., Copin, M.C., Wallaert, B., Glowacki, F., and Dewaeles, E. (2013). miR-199a-5p is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003291"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ncomms2808","article-title":"Deletion of cavin genes reveals tissue-specific mechanisms for morphogenesis of endothelial caveolae","volume":"4","author":"Hansen","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14327","DOI":"10.1038\/s41598-018-32309-1","article-title":"Anti-fibrotic impact of Carvedilol in a CCl-4 model of liver fibrosis via serum microRNA-200a\/SMAD7 enhancement to bridle TGF-\u03b21\/EMT track","volume":"8","author":"Rahmo","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14851","DOI":"10.1074\/jbc.M111.314922","article-title":"Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury","volume":"287","author":"Zhang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_63","first-page":"1468","article-title":"ZEB1 causes the production of hsa-microRNA-99b\/let-7e\/microRNA-125a cluster and promotes invasion of liver cancer cells","volume":"23","author":"Wang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/CBM-140451","article-title":"Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma","volume":"15","author":"Wang","year":"2015","journal-title":"Cancer Biomark."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1515\/jbcpp-2017-0011","article-title":"Sildenafil, a phosphodiesterase-5 inhibitor, offers protection against carbon tetrachloride-induced hepatotoxicity in rat","volume":"29","author":"Molehin","year":"2018","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kreisel, W., Schaffner, D., Lazaro, A., Trebicka, J., Merfort, I., Schmitt-Graeff, A., and Deibert, P. (2020). Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176223"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2036.2010.04366.x","article-title":"Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease","volume":"32","author":"Estep","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","first-page":"327","article-title":"Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease. Diabetes Res","volume":"99","author":"Zhang","year":"2013","journal-title":"Clin. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4254\/wjh.v6.i8.613","article-title":"Circulating microRNAs in patients with non-alcoholic fatty liver disease","volume":"6","author":"Celikbilek","year":"2014","journal-title":"World J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/2211536607666180531093302","article-title":"Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"7","author":"Jampoka","year":"2018","journal-title":"Microrna"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jhep.2018.08.008","article-title":"miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"69","author":"Liu","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.3748\/wjg.v25.i42.6322","article-title":"MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes","volume":"25","author":"Elemeery","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bbrc.2018.12.061","article-title":"Upregulation of miR-181a impairs lipid metabolism by targeting PPAR\u03b1 expression in nonalcoholic fatty liver disease","volume":"508","author":"Huang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep4.1501","article-title":"Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD","volume":"4","author":"Ezaz","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41065-020-00136-y","article-title":"Relationship between circulating miR-132 and non-alcoholic fatty liver disease in a Chinese population","volume":"157","author":"Zong","year":"2020","journal-title":"Hereditas"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"21510","DOI":"10.1038\/srep21510","article-title":"Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients","volume":"6","author":"Butt","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Afonso, M.B., Rodrigues, P.M., Sim\u00e3o, A.L., and Castro, R.E. (2016). Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J. Clin. Med., 5.","DOI":"10.3390\/jcm5030030"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/apt.13432","article-title":"Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma","volume":"43","author":"Ottosen","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"E160","DOI":"10.1016\/S0618-8278(19)30284-1","article-title":"LBP-40-Development of Oligonucleotide-Based miR-132 Antagonists for the Treatment of NASH","volume":"68","author":"Papazyan","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: Reporting in vivo experiments: The ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1111\/bph.12955","article-title":"Implementing guidelines on reporting research using animals (ARRIVE etc.): New requirements for publication in BJP","volume":"172","author":"McGrath","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1038\/s41598-020-60336-4","article-title":"Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5\/6 nephrectomy","volume":"10","author":"Wiech","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: New guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"Br. J. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:44Z","timestamp":1760179724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/1\/382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22010382"],"URL":"https:\/\/doi.org\/10.3390\/ijms22010382","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}